Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials
Annals of Pharmacotherapy · 2024
DOI: 10.1177/10600280231188171 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Hong Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Different clinical trials for recurrent or metastatic nasopharyngeal carcinoma have studied different combinations of immuno-oncology in first-line treatment, but the optimal choice has not been determined.
Objective
To systematically examine and compare the efficacy and safety of different immune checkpoint inhibitors (ICIs) combined with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Methods
Several electronic databases were systematically searched up to February 2023. Articles meeting the inclusion criteria were included.
Results
Three RCTs were eligible in the study. Compared with placebo plus gemcitabine-cisplatin (GP), toripalimab plus GP (HR = 0.59, 95% CI: 0.37-0.95) was significantly associated with a better OS. Tislelizumab plus GP generated best progression-free survival (PFS) benefit (HR = 0.50, 95% CI: 0.37-0.67), greatest improvement in 1-year PFS rate (RR = 3.00, 95% CI: 1.84-5.22), and objective response rate (ORR) (RR = 1.26, 95% CI: 1.04-1.53) over the placebo plus GP. Furthermore, tislelizumab plus GP appeared to be safer than toripalimab plus GP and camrelizumab plus GP in terms of adverse events (AEs)-grade ≥3, treatment-related AEs (TRAEs)-grade ≥3, serious AEs (SAEs), treatment-related SAEs (TRSAEs), and AEs leading to discontinuation of treatment. Conclusion and Relevance In recurrent or metastatic nasopharyngeal carcinoma, programmed death 1 (PD-1) inhibitors plus GP as first-line treatment have better survival outcomes than placebo plus GP with comparable toxicity. Toripalimab plus GP shows the best OS benefit over placebo plus GP, while tislelizumab plus GP generates the best PFS, 1-year PFS rate, ORR, and safety. Tislelizumab plus GP could be the best choice among the ICIs combined with chemotherapy regimens as first-line treatment in recurrent or metastatic nasopharyngeal carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Hong Sun
Zitieren
APA
Sun, H., Bu, F., Li, L., Zhang, X., Xin, X., Yan, J., & Huang, T. (2024). Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231188171
Vancouver
Sun H, Bu F, Li L, Zhang X, Xin X, Yan J, et al. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231188171
BibTeX
@article{Sun2024,
author = {Sun, Hong and Bu, Fengjiao and Li, Ling and Zhang, Xiuwen and Xin, Xiu and Yan, Jingchao and Huang, Taomin},
title = {Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials},
journal = {Annals of Pharmacotherapy},
year = {2024},
doi = {10.1177/10600280231188171}
}
EUVIMED